Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1993-3-26
|
pubmed:abstractText |
We studied the effectiveness of and compliance with the use of cholestyramine in children with heterozygous familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCHL). During a 10-year period, 673 children (aged 10.5 +/- 4.0 years) were referred for evaluation of hyperlipidemia, of whom 87 (36 with FH; 51 with FCHL) were treated with cholestyramine (8 to 24 gm/day). In both groups, total cholesterol, low-density lipoprotein (LDL)-cholesterol, and apolipoprotein B levels were significantly reduced after cholestyramine use. In those with FH, plasma LDL-cholesterol levels decreased from 258 +/- 35 mg/dl (6.67 +/- 0.90 mmol/L) to 190 +/- 31 mg/dl (4.91 +/- 0.80 mmol/L); in those with FCHL, LDL-cholesterol levels dropped from 207 +/- 40 mg/dl (5.35 +/- 1.03 mmol/L) to 141 +/- 35 mg/dl (3.64 +/- 0.90 mmol/L). High-density lipoprotein-cholesterol levels were not significantly changed after cholestyramine use in either group. In the FCHL group, plasma triglyceride levels increased significantly from 81 +/- 35 mg/dl (0.92 +/- 0.40 mmol/L) to 134 +/- 42 mg/dl (1.52 +/- 0.48 mmol/L). Seven patients were lost to follow-up; 18 discontinued the medication within 1 month. Of the remaining 62 children, 59 had a good response to the drug. Of the 62 patients, 52 discontinued the medication after 21.9 +/- 10 months. Adverse effects included foul taste (73%), nausea with bloating (18%), and constipation. Cholestyramine is effective in reducing LDL-cholesterol levels in children with inherited hyperlipidemia, but the majority of children will not comply with its long-term use.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins B,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholestyramine Resin,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0022-3476
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
122
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
477-82
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8441109-Adolescent,
pubmed-meshheading:8441109-Apolipoproteins B,
pubmed-meshheading:8441109-Child,
pubmed-meshheading:8441109-Cholesterol,
pubmed-meshheading:8441109-Cholesterol, HDL,
pubmed-meshheading:8441109-Cholesterol, LDL,
pubmed-meshheading:8441109-Cholestyramine Resin,
pubmed-meshheading:8441109-Follow-Up Studies,
pubmed-meshheading:8441109-Humans,
pubmed-meshheading:8441109-Hyperlipidemia, Familial Combined,
pubmed-meshheading:8441109-Patient Compliance,
pubmed-meshheading:8441109-Triglycerides
|
pubmed:year |
1993
|
pubmed:articleTitle |
Use of cholestyramine in the treatment of children with familial combined hyperlipidemia.
|
pubmed:affiliation |
Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia, PA 19104.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|